Structure Therapeutics (GPCR) EBIT (2022 - 2026)

Structure Therapeutics' EBIT history runs 5 years deep, the most recent figure standing at -$89.4 million for Q1 2026.

• In Q1 2026, EBIT fell 58.72% year-over-year to -$89.4 million; the TTM figure through Mar 2026 stood at -$62.6 million (down 25.32% YoY), while the FY2025 annual figure was -$29.5 million, down 15.11% from the prior year.
• EBIT was -$89.4 million for Q1 2026 at Structure Therapeutics, down from $171.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $171.0 million in Q4 2025 to a low of -$89.4 million in Q1 2026.
• Historically, EBIT has averaged -$17.6 million across 5 years, with a median of -$26.1 million in 2023.
• The sharpest annual moves came in 2023 and 2024: EBIT tumbled 139.23% in 2023, then jumped 375.87% in 2024.
• A 5-year view of EBIT shows it stood at -$13.0 million in 2022, then sank by 139.23% to -$31.0 million in 2023, then jumped by 375.87% to $85.5 million in 2024, then surged by 100.0% to $171.0 million in 2025, then plunged by 152.27% to -$89.4 million in 2026.
• The last three EBIT figures came in at -$89.4 million (Q1 2026), $171.0 million (Q4 2025), and -$73.8 million (Q3 2025), per Business Quant data.